辐射聚合FT-207的体内释放研究  

IN VIVO RELEASE OF FT-207 FROM IRRADIATION POLYMERIZED COMPOSITES

作　　者：谢怀江[1] 寇庆河[1] 宋聚忠[1] 彭涛[1] 陈晓晖 张德喜 

机构地区：[1]沈阳军区军事医学研究所,沈阳110031 [2]辽宁省分析测试中心,沈阳110015

出　　处：《辐射研究与辐射工艺学报》1999年第1期28-30,共3页Journal of Radiation Research and Radiation Processing

基　　金："八五"全军青年基金

摘　　要：对室温下辐射聚合制备的药物缓释系统进行了体内研究，家兔背部皮下埋植FT-207聚合体，用HPLC测定，结果显示FT-207聚合物埋植组1周后血清药物浓度为1μg／mL，其聚合体周围组织药物浓度达76±10．4μg／mL，而远隔器官较低（如肺脏仅1．2±0.5μg／mL）。与口服、静脉、腹腔给药等常规方式相比。证实采用常规给药方法血清药物浓度较高且持续时间短，包埋缓释药物血清浓度较低、持续时间较长。Polymer-drugs composite with long periods of controlled slow release was made by radiation induced polymerization in room temperature. In experiment in vivo, the composite were implanted subcutaneously the back of rabbits. The concentration of 1-(2-tetrahydrofuryl)-5-fluorouracil(FT-207) was determined by HPLC. The results of test showed that the concentration of serum drug is 1.0μg/mL after 1 week in the polymer-drug composites group. The drug concentration of tissue surrouding the composites is 76.2±10.4μg/mL. The drug concentration in the far organ (e.g.the lung 1.2±0.5μg/mL) is lower than the tissue surrounding the composite. The serum drug is higher and shorter time by the routine methods. The serum concentration of FT-207 is lower and retarded by implanted.

关 键 词：辐射聚合 缓解药 呋喃氟脲嘧啶 肿瘤药 体内释放 

分 类 号：R979.1[医药卫生—药品]